IL99225A - 3- or 5-amidopyrazole derivatives their preparation and pharmaceutical compositions containing them - Google Patents

3- or 5-amidopyrazole derivatives their preparation and pharmaceutical compositions containing them

Info

Publication number
IL99225A
IL99225A IL9922591A IL9922591A IL99225A IL 99225 A IL99225 A IL 99225A IL 9922591 A IL9922591 A IL 9922591A IL 9922591 A IL9922591 A IL 9922591A IL 99225 A IL99225 A IL 99225A
Authority
IL
Israel
Prior art keywords
group
alkyl
substituted
formula
atom
Prior art date
Application number
IL9922591A
Other languages
English (en)
Other versions
IL99225A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL99225A0 publication Critical patent/IL99225A0/xx
Publication of IL99225A publication Critical patent/IL99225A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL9922591A 1990-08-20 1991-08-19 3- or 5-amidopyrazole derivatives their preparation and pharmaceutical compositions containing them IL99225A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9010486A FR2665898B1 (fr) 1990-08-20 1990-08-20 Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.

Publications (2)

Publication Number Publication Date
IL99225A0 IL99225A0 (en) 1992-07-15
IL99225A true IL99225A (en) 1995-10-31

Family

ID=9399742

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9922591A IL99225A (en) 1990-08-20 1991-08-19 3- or 5-amidopyrazole derivatives their preparation and pharmaceutical compositions containing them

Country Status (31)

Country Link
US (6) US5420141A (cs)
EP (1) EP0477049B1 (cs)
JP (1) JP2694932B2 (cs)
KR (1) KR100223074B1 (cs)
AR (1) AR248133A1 (cs)
AT (1) ATE187167T1 (cs)
AU (1) AU646683B2 (cs)
BR (1) BR9103550A (cs)
CA (4) CA2166901C (cs)
CZ (1) CZ281864B6 (cs)
DE (1) DE69131813T2 (cs)
DK (1) DK0477049T3 (cs)
ES (1) ES2142798T3 (cs)
FI (1) FI104170B1 (cs)
FR (1) FR2665898B1 (cs)
GR (1) GR3032732T3 (cs)
HU (2) HU217435B (cs)
IE (1) IE912932A1 (cs)
IL (1) IL99225A (cs)
LT (1) LT3520B (cs)
LV (1) LV10434B (cs)
MX (1) MX9203576A (cs)
MY (1) MY121908A (cs)
NO (1) NO300212B1 (cs)
NZ (1) NZ239476A (cs)
PL (1) PL169085B1 (cs)
PT (1) PT98717B (cs)
RU (1) RU2066317C1 (cs)
SG (1) SG52322A1 (cs)
TW (1) TW366337B (cs)
ZA (1) ZA916583B (cs)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2713224B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5668279A (en) * 1992-11-02 1997-09-16 Merck & Co., Inc. Substituted phthalazinones as neurotensin antagonists
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
US6716991B1 (en) 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
ATE219937T1 (de) * 1993-11-30 2002-07-15 Searle & Co Substitutierte pyrazolyl-benzolsulfonamide zur verwendung in der behandlung von entzündungen
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2722193B1 (fr) * 1994-07-08 1996-10-04 Sanofi Sa Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
ZA9711102B (en) * 1996-12-16 1998-08-13 Yamanouchi Pharma Co Ltd N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative
CA2281946C (en) * 1997-03-03 2007-08-07 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
US5776987A (en) * 1997-03-03 1998-07-07 Sanofi Pharmaceuticals, Inc. Pharmaceutical suspension formulation
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
US5760056A (en) * 1997-03-03 1998-06-02 Sanofi Pharmaceuticals, Inc. Pharmaceutical formulation
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ATE266399T1 (de) * 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
EP1126852B1 (en) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
ES2241675T3 (es) 1999-11-23 2005-11-01 Smithkline Beecham Corporation Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2001264694B8 (en) * 2000-05-19 2006-05-04 Laboratoires Serono Sa Use of pyrazole derivatives for treating infertility
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
WO2003027075A2 (en) 2001-09-19 2003-04-03 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
CA2460942A1 (en) 2001-09-19 2003-03-27 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
DE10146867A1 (de) * 2001-09-24 2003-04-24 Bayer Ag Tetrahydroisochinoline
CA2458661A1 (en) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methods of increasing endogenous testosterone levels
AR038967A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de 2,3 - diaril - pirazolidinas como inhibidores de enzimas que degradan la neurotensina
WO2004016741A2 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1433788A1 (en) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
KR20050096956A (ko) * 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
MXPA05011922A (es) * 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1670460B1 (en) * 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE602005016082D1 (de) * 2004-02-20 2009-10-01 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
MX2007000016A (es) * 2004-07-01 2007-03-27 Daiichi Seiyaku Co Derivados de pirazol.
EP1831177A1 (en) * 2004-12-23 2007-09-12 AstraZeneca AB Therapeutic agents
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
RU2425677C2 (ru) * 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2006133926A1 (en) * 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US20100004243A1 (en) * 2006-07-14 2010-01-07 Astex Therapeutics Limited Pharmaceutical compounds
GB0619611D0 (en) * 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
CA2673359A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US8133904B2 (en) 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2009051772A1 (en) * 2007-10-17 2009-04-23 Duke University Geranylgeranyl transferase inhibitors and methods of making and using the same
KR100917037B1 (ko) * 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
CN102250006B (zh) * 2011-05-12 2014-03-05 范如霖 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
WO2015148465A1 (en) * 2014-03-25 2015-10-01 Research Triangle Institute Pyrazole compounds selective for neurotensin 2 receptor
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
JP2019501899A (ja) * 2015-12-09 2019-01-24 リサーチ トライアングル インスティテュート 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CA3145074A1 (en) * 2019-08-29 2021-03-04 Research Triangle Institute Methods and uses for apelin receptor agonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134987A (en) * 1976-01-14 1979-01-16 Huppatz John L Compounds and compositions
JPS584771A (ja) * 1981-06-26 1983-01-11 ワ−ナ−−ランバ−ト・コンパニ− （５−アミノ−１，３−ジアルキルピラゾ−ル−４−イル）（アリ−ル）メタノンの塩基性アシルアミド類
US4495195A (en) * 1982-11-01 1985-01-22 Eli Lilly And Company Xanthine oxidase inhibiting 3(5)-phenyl-substituted-5(3)-pyrazole-carboxylic acid derivatives, compositions, and methods of use
DE3332633A1 (de) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituierte carbonsaeurederivate, verfahren zu ihrer herstellung, und arzneimittel
IL73419A (en) * 1983-11-07 1988-02-29 Lilly Co Eli 1h-pyrazole-4-(thio)carboxamide derivatives,their preparation and herbicidal compositions containing them
JPS611651A (ja) * 1984-06-12 1986-01-07 Toyama Chem Co Ltd Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
KR920003893B1 (ko) * 1984-10-29 1992-05-18 스미또모가가꾸고오교 가부시끼가이샤 피라졸 카르복스아미드 유도체의 제조방법
JPH0678342B2 (ja) * 1986-01-07 1994-10-05 三共株式会社 新規マクロライド化合物
US4792565A (en) * 1986-04-24 1988-12-20 Mitsui Toatsu Chemicals, Inc. Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4916142A (en) * 1987-02-02 1990-04-10 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics
US4954506A (en) * 1987-02-02 1990-09-04 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
US4912109A (en) * 1987-02-02 1990-03-27 Boc, Inc. N-heterocyclic-N-(4-piperidinyl) amides and pharmaceutical compositions and methods employing such compounds
US4791112A (en) * 1987-02-02 1988-12-13 The Boc Group, Inc. N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
JPS6425763A (en) * 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
US4971978A (en) * 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
AU2793389A (en) * 1987-11-30 1989-07-05 E.I. Du Pont De Nemours And Company Heterocyclic pyrazoline carboxanilides
JP2861104B2 (ja) * 1988-10-14 1999-02-24 三菱化学株式会社 ピラゾールアミド類およびこれを有効成分とする殺虫、殺ダニ剤
WO1990014347A1 (fr) * 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Derives d'indole et medicament

Also Published As

Publication number Publication date
NO913234D0 (no) 1991-08-19
DE69131813D1 (de) 2000-01-05
EP0477049A1 (fr) 1992-03-25
CA2166903A1 (en) 1992-02-21
HUT59106A (en) 1992-04-28
KR920004354A (ko) 1992-03-27
CA2166902C (en) 1999-01-19
GR3032732T3 (en) 2000-06-30
PL169085B1 (pl) 1996-05-31
DE69131813T2 (de) 2000-05-31
LV10434A (lv) 1995-02-20
DK0477049T3 (da) 2000-04-25
CS257491A3 (en) 1992-06-17
HU912750D0 (en) 1992-01-28
HU217435B (hu) 2000-01-28
US5744493A (en) 1998-04-28
AR248133A1 (es) 1995-06-30
PT98717A (pt) 1992-07-31
US5607958A (en) 1997-03-04
CA2166903C (en) 1998-09-01
MY121908A (en) 2006-03-31
CA2049514C (en) 1997-02-25
CA2166901C (en) 1999-01-26
KR100223074B1 (ko) 1999-10-15
TW366337B (en) 1999-08-11
PL291463A1 (en) 1992-07-13
CA2166901A1 (en) 1992-02-21
IL99225A0 (en) 1992-07-15
AU646683B2 (en) 1994-03-03
FI104170B (fi) 1999-11-30
FI913917A0 (fi) 1991-08-19
LTIP656A (en) 1995-01-31
IE912932A1 (en) 1992-02-26
JP2694932B2 (ja) 1997-12-24
PT98717B (pt) 1999-01-29
AU8259691A (en) 1992-02-27
MX9203576A (es) 1992-07-01
US5744491A (en) 1998-04-28
FR2665898B1 (fr) 1994-03-11
SG52322A1 (en) 1998-09-28
FI104170B1 (fi) 1999-11-30
LV10434B (en) 1995-10-20
FR2665898A1 (fr) 1992-02-21
LT3520B (en) 1995-11-27
ZA916583B (en) 1992-05-27
CA2049514A1 (en) 1992-02-21
ATE187167T1 (de) 1999-12-15
HK1005136A1 (en) 1998-12-24
JPH04244065A (ja) 1992-09-01
US5420141A (en) 1995-05-30
US5616592A (en) 1997-04-01
EP0477049B1 (fr) 1999-12-01
HU211970A9 (en) 1996-01-29
BR9103550A (pt) 1992-04-07
US5635526A (en) 1997-06-03
CZ281864B6 (cs) 1997-03-12
ES2142798T3 (es) 2000-05-01
NO300212B1 (no) 1997-04-28
FI913917A7 (fi) 1992-02-21
NZ239476A (en) 1993-11-25
NO913234L (no) 1992-02-21
RU2066317C1 (ru) 1996-09-10
CA2166902A1 (en) 1992-02-21

Similar Documents

Publication Publication Date Title
IL99225A (en) 3- or 5-amidopyrazole derivatives their preparation and pharmaceutical compositions containing them
CA2274594C (en) Aminopyrazole derivatives
EP0945438B1 (en) Pyrazole derivatives
HU222724B1 (hu) Eljárás 3-amino-2-fenil-piperidin elżállítására
JP2001518504A (ja) ５ｈｔ４作動薬および拮抗薬
CA2273102A1 (en) Urea derivatives
NO338263B1 (no) Imidazolforbindelser, farmasøytiske sammensetninger inneholdende slike, og anvendelse derav for behandling av en sykdom eller tilstand assosiert med modulering av Notch signaliseringsreaksjonsveien
US6166038A (en) Aminopyrazole derivatives
JP2018510131A (ja) Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法
CN118632834A (zh) 用于治疗神经变性疾病的含有羧酸的茚满基化合物
WO2006068591A1 (en) Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
IL96384A (en) Pyridazine derivatives their preparation and pharmaceutical compositions containing them
CA2524019A1 (en) Positive modulators of nicotinic acetylcholine receptors
HUP0003997A2 (en) 3-benzylpiperidine derivatives, pharmaceutical compositions containing them and process for producing them
CA2805219A1 (en) Pyrazole compound
Vraničar et al. Synthesis and transformations of a pyrazole containing α, β-didehydro-α-amino acid derivatives
MX2011008578A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en posicion 3, su preparacion y su uso en terapeutica.
JPH04234369A (ja) ６−アルキルピリダジン誘導体、調製方法およびそれらを含有する医薬組成物
HK1005136B (en) Amido-3-pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
JP2025501761A (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators
CZ176895A3 (cs) Substituované N-oxidované deriváty l-(7-chlorchinolein-4-yl)-pyrazoI-3-karboxamidů, způsob jejich přípravy a farmaceutické přípravky sjejich obsahem

Legal Events

Date Code Title Description
FF Patent granted
HE Change of address of proprietor(s)
KB Patent renewed
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees